https://transhumanist.ru/index.php?action=history&feed=atom&title=ABL1 2026-06-07T22:39:43Z История изменений этой страницы в вики MediaWiki 1.43.6 https://transhumanist.ru/index.php?title=ABL1&diff=5783&oldid=prev 2021-05-12T14:51:21Z

<p>Новая страница: «Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150) [A...»</p> <p><b>Новая страница</b></p><div>Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150) [ABL] [JTK7]<br /> <br /> ==Publications==<br /> <br /> {{medline-entry<br /> |title=European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.<br /> |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/32127639<br /> |abstract=The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase ([[CP]]) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in [[CP]]. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% [[BCR]]-[[ABL1]] at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.<br /> |mesh-terms=* Aniline Compounds<br /> * Antineoplastic Agents<br /> * Clinical Decision-Making<br /> * Consensus Development Conferences as Topic<br /> * Dasatinib<br /> * Disease Management<br /> * Fusion Proteins, bcr-abl<br /> * Gene Expression<br /> * Humans<br /> * Imatinib Mesylate<br /> * Leukemia, Myelogenous, Chronic, BCR-ABL Positive<br /> * Life Expectancy<br /> * Monitoring, Physiologic<br /> * Nitriles<br /> * Protein Kinase Inhibitors<br /> * Pyrimidines<br /> * Quality of Life<br /> * Quinolines<br /> * Survival Analysis<br /> <br /> |full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214240<br /> }}</div>

OdysseusBot